ERBB2 and breast cancer: The HER2-enriched subtype, accounting for approximately 20% of BC cases, includes HR-negative, HER2-positive tumors with a HER2 immunohistochemical score of 3+ or 2+ and confirmed gene amplification by in situ hybridization (ISH) [22].